Therapy- induced clearance of HCV core antigen from plasma predicts an end of treatment viral response

Journal of Viral Hepatitis

Volumn 20, Issue 1, 2013, Pages 65-71

  Tedder, R S ^a,b   Tuke, P ^a   Wallis, N ^a   Wright, M ^c   Nicholson, L ^d   Grant, P R ^e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

HCV RNA; HCVp22Ag; Hepatitis C; prediction EOTR

Indexed keywords

INTERFERON; RIBAVIRIN; VIRUS ANTIGEN; VIRUS RNA;

ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL LOAD;

EID: 84871011601     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01630.x     Document Type: Article

References (19)

1. Takahashi K, Okamoto H, Kishimoto S, et al. Demonstration of a hepatitis C virus- specific antigen predicted from the putative core gene in the circulation of infected hosts. J Gen Virol 1992; 3: 667-672.
2. Tanaka E, Kiyosawa K, Matsumoto A, et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1996; 23: 1330-1333.
3. Aoyagi K, Ohue C, Iida K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37: 1802-1808.
4. Tanaka E, Ohue C, Aoyagi K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000; 32: 388-393.
5. Nubling CM, Unger G, Chudy M, Raia S, Lower J,. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002; 42: 1037-1045.
6. Muerhoff AS, Jiang L, Shah DO, et al. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 2002; 42: 349-356.
7. Morota K, Fujinami R, Kinukawa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009; 157: 8-14.
8. Wright M, Forton D, Main J, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005; 12: 58-66.
9. Saldanha J, Lelie N, Heath A,. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999; 76: 149-158.
10. Dickson RC, Mizokami M, Orito E, Qian KP, Lau JY,. Quantification of serum HCV core antigen by a fluorescent enzyme immunoassay in liver transplant recipients with recurrent hepatitis C- - clinical and virologic implications. Transplantation 1999; 68: 1512-1516.
11. Mederacke I, Wedemeyer H, Ciesek S, et al. Performance and clinical utility of a novel fully automated quantitative HCV- core antigen assay. J Clin Virol 2009; 46: 210-215.
12. Medici MC, Furlini G, Rodella A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011; 51: 264-269.
13. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J,. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010; 48: 18-21.
14. Laperche S, Elghouzzi MH, Morel P, et al. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 2005; 45: 1965-1972.
15. Laperche S, Le Marrec N, Girault A, et al. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti- HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43: 3877-3883.
16. Letowska M, Rosiek A, Gronowska A, Mikulska M, Grabarczyk P, Brojer E,. Hepatitis C virus (HCV) core antigen detection in HCV RNA- positive/anti- HCV- negative Polish blood donors identified by nucleic acid testing. Transfusion 2009; 49: 2241-2242.
17. Carabaich A, Ruvoletto M, Bernardinello E, et al. Profiles of HCV core protein and viremia in chronic hepatitis C: possible protective role of core antigen in liver damage. J Med Virol 2005; 76: 55-60.
18. Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M,. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010; 48: 1161-1168.
19. Chapko MK, Sloan KL, Davison JW, et al. Cost effectiveness of testing strategies for chronic hepatitis C. Am J Gastroenterol 2005; 100: 607-615.